LifeMD Inc

Análisis de la acción LifeMD Inc (LFMD)

$2.290

-0.150 (-6.53%)Al cierre

Loading chart…
Máximo
2.490
Apertura
2.460
Precio medio ponderado por volumen
2.33
Volumen
597.21K
Capitalización
279.29M
Mínimo
2.205
Importe
1.39M
EV/EBITDA, TTM
-3.54

LifeMD, Inc. is a patient-centric, direct-to-patient healthcare company. The Company is engaged in providing patients access to virtual medical care and pharmacy services. Its telehealth platform helps patients access licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis and sells over the counter (OTC) products. Its products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. The Company's men's brand, RexMD, offers access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation and hair loss. Its vertically integrated care model combines technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence (AI)-enabled operational systems to deliver longitudinal care.

lifemd.com

Análisis de IA of LifeMD Inc (LFMD)

Comprar

LifeMD Inc appears to be a good buy right now due to its current price of $2.31, which is significantly below its 52-week high of $5.73, indicating potential for upside. The stock has a forward P/E ratio of 12.85, suggesting it may be undervalued compared to future earnings. Additionally, the RSI is at 55.54, indicating the stock is neither overbought nor oversold, which is a favorable technical indicator. However, the main risk is the company's net income, which has been negative, with a reported loss of $9.64 million in Q1 2026, highlighting ongoing financial challenges.

Métricas de valoración

El PER previsto actual de LifeMD Inc (LFMD) es 12.85, frente a su media de 5 años de -15.58.

PER previsto

Valor razonable
Media 5A P/E
-15.58
P/E actual
12.85
Sobrevalorada
43.95
Infravalorada
-75.10

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
5.86
EV/EBITDA actual
-3.54
Sobrevalorada
18.37
Infravalorada
-6.64

Precio/ventas previsto

Infravalorado
Media 5A P/S
0.93
P/S actual
0.48
Sobrevalorada
1.37
Infravalorada
0.49

Escenarios de precio de Alphio AI para LFMD

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%LFMD

$14.58

Precio del escenario

B

Base

Base · 50%LFMD

$13.42

Precio del escenario

B

Bajista

Bajista · 25%LFMD

$9.37

Precio del escenario

Cronología de eventos

2026-11-05 (ET)

10:00:00

LifeMD Partners with Eli Lilly for Direct GLP-1 Drug Dispensing

2026-09-17 (ET)

12:00:00

H.C. Wainwright Gives LifeMD Buy Rating, Price Target $9

2026-08-05 (ET)

18:30:00

LifeMD Sees Q3 Adjusted EBITDA Loss of $1M to Gain of $2M

18:30:00

LifeMD Cuts FY26 Revenue Outlook to $6B Loss

Noticias

Preguntas frecuentes sobre LFMD, respondidas por Alphio AI

LifeMD, Inc. is a patient-centric, direct-to-patient healthcare company. The Company is engaged in providing patients access to virtual medical care and pharmacy services. Its telehealth platform helps patients access licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis and sells over the counter (OTC) products. Its products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. The Company's men's brand, RexMD, offers access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation and hair loss. Its vertically integrated care model combines technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence (AI)-enabled operational systems to deliver longitudinal care. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).

LifeMD Inc appears to be a good buy right now due to its current price of $2.31, which is significantly below its 52-week high of $5.73, indicating potential for upside. The stock has a forward P/E ratio of 12.85, suggesting it may be undervalued compared to future earnings. Additionally, the RSI is at 55.54, indicating the stock is neither overbought nor oversold, which is a favorable technical indicator. However, the main risk is the company's net income, which has been negative, with a reported loss of $9.64 million in Q1 2026, highlighting ongoing financial challenges.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar